Market Indices
Sector Heatmap
DYN — Dyne Therapeutics, Inc. Common Stock
NasdaqDyne Therapeutics, Inc. Common Stock
- O
- 16.03
- H
- 16.03
- L
- 15.09
- V
- 2.5M
DYN — Latest News & Headlines
18 StoriesWall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes Stocktwits
Dyne Therapeutics stock rises on positive DM1 trial results - Yahoo! Finance Canada
Dyne Therapeutics stock rises on positive DM1 trial results Yahoo! Finance Canada
After a year, Dyne trial participants showed better walking-test times and muscle strength - Stock Titan
After a year, Dyne trial participants showed better walking-test times and muscle strength Stock Titan
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN) - Seeking Alpha
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN) Seeking Alpha
Is Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations? - Simply Wall Street
Is Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations? Simply Wall Street
DYN Maintained by HC Wainwright & Co. -- Price Target Lowered to $32 - GuruFocus
DYN Maintained by HC Wainwright & Co. -- Price Target Lowered to $32 GuruFocus
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock Stocktwits
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) The Globe and Mail
(DYN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
(DYN) Movement Within Algorithmic Entry Frameworks news.stocktradersdaily.com
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions - Investing.com
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions Investing.com
BNPPF Private Harm Dyn Class Sel 1 Dis (0P0001BV2R.F) stock price, news, quote and history - Yahoo Finance UK
BNPPF Private Harm Dyn Class Sel 1 Dis (0P0001BV2R.F) stock price, news, quote and history Yahoo Finance UK
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target - TradingView
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target TradingView
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data? - Simply Wall Street
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data? Simply Wall Street
CytoDyn (CYDY) amends two registrations covering 279M and 278M common shares to remove what remains unsold. - Stock Titan
CytoDyn (CYDY) amends two registrations covering 279M and 278M common shares to remove what remains unsold. Stock Titan
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) The Globe and Mail
Jefferies reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com India
Jefferies reiterates Dyne Therapeutics stock rating on trial data By Investing.com Investing.com India
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Stocktwits
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space Stocktwits
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating By Investing.com Investing.com UK